-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $12

Benzinga·11/17/2026 15:23:23
Listen to the news
Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $13 to $12.